CXCL8 and neoplasm: In our study, secretion of IL-6, IL-8, MMP-9, PDGF-BB, IL-1β, G-CSF, and CCL-2 by ccRCC immune cells in tumor microenvironment were able to overcome the anti-angiogenic effects of cabozantinib.